EXPERIMENTAL STUDY

Effects of insulin-like growth factor-I treatment on the endocrine pancreas of hypophysectomized rats: comparison with growth hormone replacement

T Jevdjovic, C Maake, E Eppler, E Zoidis, M Reinecke and J Zapf

Division of Neuroendocrinology, Institute of Anatomy, University of Zurich, Winterthurerstr. 190, CH-8057 Zurich, 1Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital of Zurich, Ramistr. 100, CH-8091 Zurich, Switzerland

(Correspondence should be addressed to J Zapf; Email: juergen.zapf@usz.ch)

Abstract

Background: In GH-deficient humans, GH and IGF-I treatment cause opposite effects on serum insulin concentrations and insulin sensitivity. This finding contrasts with the somatomedin hypothesis that IGF-I mediates GH action, as postulated for skeletal growth, and raises the question whether GH-induced IGF-I acts on the endocrine pancreas in the same way as administered IGF-I.

Objective: To compare the effects of the two hormones on the endocrine pancreas of hypophysectomized rats.

Methods: Animals were infused for 2 days, via miniosmotic pumps, with IGF-I (300 µg/day), GH (200 mU/day) or vehicle. We measured (i) glucose, IGF-I, insulin, C-peptide and glucagon in serum and (ii) IGF-I, insulin and glucagon mRNAs and peptides in the pancreas by radioimmunoassay, immunohistochemistry and northern analysis.

Results: Both GH and IGF-I treatment increased serum and pancreatic IGF-I but, unlike GH, IGF-I treatment strongly reduced serum insulin and C-peptide (and, to a lesser extent, serum glucagon). Nevertheless, the animals did not become hyperglycaemic. GH, but not IGF-I, increased pancreatic insulin and glucagon content, as also indicated by immunohistochemistry, and increased IGF-I mRNA. Neither GH nor IGF-I caused significant changes in insulin and glucagon mRNA.

Conclusions: The decrease in serum insulin and C-peptide by IGF-I treatment without significant changes in insulin gene expression and pancreatic insulin content suggests inhibition of insulin secretion. Within this setting, the absence of hyperglycaemia points to enhanced insulin sensitivity, although an insulin-like action of infused IGF-I may have partially compensated for the decreased insulin concentrations. GH-induced circulating or pancreatic IGF-I, or both, does not mimic the pancreatic effects of infused IGF-I in the absence of GH, suggesting that GH may counteract the action of GH-induced IGF-I on the endocrine pancreas.

European Journal of Endocrinology 151 223–231

Introduction

It is generally accepted that insulin-like growth factor (IGF)-I mediates the effects of growth hormone (GH) on tissues concerned with growth. Most of the IGF-I in the circulation is synthesized and released by the liver under the influence of GH but, in addition, GH also stimulates the production of IGF-I in extrahepatic tissues, thereby increasing its local concentration (1, 2). The relative contributions of circulating and locally produced IGF-I in mediating the effects of GH remain a matter of debate (3, 4).

Another question is whether or not other effects of GH, such as those on the endocrine pancreas and on glucose homeostasis, are also mediated by the action of circulating or locally produced IGF-I, or whether these effects are direct and, thus, independent of IGF-I. The latter view is supported by the findings of a study in GH-deficient humans treated for several days with IGF-I, GH or a combination of both hormones (5), which showed that IGF-I suppressed serum insulin and C-peptide concentrations and increased insulin sensitivity, whereas GH increased serum insulin and C-peptide concentrations and decreased insulin sensitivity. IGF-I in conjunction with GH treatment counteracted these effects of GH.

In contrast, studies in mice in which the IGF-I gene in the liver had been deleted and in which the serum IGF-I concentrations were decreased by more than 75% of normal, have pointed to a role of circulating IGF-I in the regulation of insulin secretion, insulin sensitivity and glucose homeostasis (6, 7). However, the changes observed in these animals, such as hyperinsulinaemia, islet cell hyperplasia and insulin insensitivity, may well have been caused by the more than sixfold increase in the serum concentrations of GH (6) as a
result of negative feedback regulation of pituitary GH secretion by low circulating IGF-I. As the expression of IGF-I mRNA in extrahepatic tissues was apparently normal (4), and not increased as one would have expected in the presence of the increased GH concentrations, one might argue that the above changes in this animal model were not mediated via IGF-I, but rather were the result of direct GH action. This is also indicated by the finding that administration of a GH-releasing hormone antagonist that reduced serum GH concentrations improved insulin sensitivity (6). Nevertheless, a direct role of IGF-I could not be excluded, because IGF-I treatment not only normalized serum GH and insulin concentrations, but also completely restored insulin sensitivity (6).

In order to reassess this issue independently of endogenous GH, we infused hypophysectomized (hypox) rats with either GH or IGF-I for 2 days via miniosmotic pumps, and compared the effects of these two hormones on the expression of IGF-I, insulin and glucagon mRNA and peptide in the pancreas, and on the serum concentrations of glucose, IGF-I, insulin, C-peptide and glucagon.

Materials and methods

Animals

All animal experiments were approved by the Institutional Animal Welfare Committee. Hypox male Wistar rats (body weight 150–160 g, age 7 weeks) were obtained from Charles River Laboratories (Charles River, Iffa Credo, France). The rats were kept at 25 °C on a cycle of 12 h light/12 h darkness and had free access to food and drinking water. Animals that gained less than 2 g during 1 week before the experiment were selected for infusion.

Infusion procedure

Alzet miniosmotic pumps (model 2001, Alza, Palo Alto, CA, USA) were filled with vehicle (0.1 mol/l acetic acid), recombinant human (rh) IGF-I (provided by Dr K Müller, Novartis Pharma AG, Basel, Switzerland) dissolved in H2O/benzyl alcohol (as provided by the supplier). The miniosmotic pumps were implanted subcutaneously in the abdomen with the miniosmotic pumps, and compared the effects of these two hormones on the expression of IGF-I, insulin and glucagon mRNA and peptide in the pancreas, and on the serum concentrations of glucose, IGF-I, insulin, C-peptide and glucagon.

Radioimmunoassays

Pancreatic and serum insulin concentrations were determined with a rat IGF-I RIA kit (Linco Research, Inc., St Charles, MO, USA). Serum C-peptide and serum and pancreatic glucagon concentrations were measured with rat C-peptide and rat glucagon RIA kits, respectively (Linco Research, Inc.). All serum concentrations were determined in undiluted samples. For the determination of pancreatic insulin and glucagon concentrations, extracts were diluted 1:2000 to 1:4000 in the assay buffer provided. Serum and tissue concentrations of administered rhIGF-I and of endogenous rat IGF-I were determined by two different RIAs with two different antisera after SepPak C18 chromatography (Waters Corp., Milford, MA, USA) of the samples, as described in detail previously (8, 9). For the determination of IGF-I in pancreatic extracts, 0.5 ml extract were lyophilized, dissolved in 0.25 ml PBS containing 0.2% human serum albumin (HSA), centrifuged and run over SepPak C18 cartridges according to the procedure supplied by Immunonuclear (Stillwater, MN, USA). After reconstitution with 0.6 ml PBS–0.2% HSA, samples were assayed at three different dilutions (undiluted, 1:2 and 1:4) in the rhIGF-I or in the rat IGF-I RIA (8, 9) using rhIGF-I or recombinant rat IGF-I (GroPop, Adelaide, Australia) respectively as standards.

In our human IGF-I RIA, rat IGF-I does not cross-react; the values obtained in this RIA therefore reflect only the concentrations of the infused rhIGF-I. In the rat RIA, human IGF-I crossreacts four to five times better than rat IGF-I, so that endogenous rat IGF-I...
IGF-I effects on the islets of hypophysectomized rats

cannot be determined in rhIGF-I-infused animals; total IGF-I concentrations in these animals can be estimated by adding mean endogenous IGF-I concentrations of hypox controls. In animals infused with GH and in the control animals (absence of rhIGF-I), the RIA values represent endogenous rat IGF-I concentrations.

Serum concentrations of infused rhGH were determined with a commercially available IRMA kit (Schering AG, Basel, Switzerland).

**Determination of blood volume in pancreatic tissue**

The amount of blood in pancreas was determined according to the technique of Hohorst et al. (10). This method is based on the assumption that the proportion of oxyhaemoglobin (HbO2) is approximately the same in circulating blood and in tissue capillaries. Briefly, 0.1 ml heparinized rat blood was diluted in 25 ml water and haemolysed for 10 min on ice. Pancreatic tissue was homogenized in water (5 ml/g). The homogenates were centrifuged at 16 000 g for 10 min at 4°C. The supernatants were transferred to fresh tubes and the pellets resuspended in water (2 ml/g) and recentrifuged. The supernatants were pooled and kept on ice. After vigorous shaking for 1 min, the absorption spectra of blood and pancreas homogenate at several dilutions were recorded between 500 and 650 nm. The absorbance differences (ΔA(HbO2) for tissue extracts and ΔA(HbO2) for blood samples) were determined by drawing a straight line between the two extinction maxima at 540 and 578 nm and a parallel line through the extinction minimum at 560 nm of the HbO2 spectra obtained for the tissue extracts and the blood dilutions, respectively. The fraction X of the blood in the tissue was calculated as follows:

\[ X = \frac{(\Delta A_{HbO2} \times F_1 \times d_1)/(\Delta A'_{HbO2} \times F_2 \times d_2)}{100(\%)} \]

where \( F_1 \) and \( F_2 \) are the dilution factors and \( d_1 \) and \( d_2 \) the respective light paths of the cuvettes.

**Immunohistochemical procedure**

Pancreas specimens were fixed in Bouin’s solution after 4 h, embedded in paraffin and processed for double immunofluorescence as described previously (11). Briefly, 4 μm pancreas sections were cut, deparaffinized and rehydrated. Non-specific binding was reduced by treatment of the sections with PBS containing 2% BSA for 30 min at room temperature and processed for double immunofluorescence. The sections were incubated with a rabbit antiserum against porcine glucagon (code: A564, 1:18 000; Dako), washed three-times with PBS–2% BSA and treated with biotinylated goat anti-porcine IgG (1:100; Bioscience, Emmenbrücke, Switzerland) and streptavidin Texas red (1:100; Amer sham, Dübendorf, Switzerland) for 30 min at room temperature. For control incubations, the primary antisera were replaced by non-immune sera or preabsorbed with the respective antigens (0.4–40 μg peptide/ml diluted antiserum). The sections were examined and photographed with a confocal laser-scanning microscope (Leica, Heidelberg, Germany).

**Preparation of cDNA probes**

Total RNA from rat pancreas (for generation of the glucagon cDNA probe) and liver (for generation of the IGF-I probe) was reverse transcribed by M-MLLV reverse transcriptase (Promega, Madison, WI, USA) in the presence of oligo(dT) primer and in 1 × reaction buffer [5 × 250 mmol/l Tris–HCl (pH 8.3), 375 mmol/l KCl, 15 mmol/l MgCl2 and 50 mmol/l dithiothreitol], according to the manufacturer’s instructions. The cDNAs were subjected to PCR. For IGF-I, the sense primer 5’-ACATCATCTGCTGCTTCCATC-3’ and the antisense-primer 5’-GGTTCTGTGTTCTCGACTTC-3’, spanning the nucleotide sequence 38–395 (GenBank Accession no. D00698), and for glucagon the sense primer 5’-AAGCAGAGCAGAAGCCATTT-3’ and the antisense primer 5’-GCGGAATTCTCCAGAGTCGAT-3’, corresponding to the nucleotide sequence 138–428 (GenBank Accession no. NO 012707) were used. The rat insulin cDNA probe (500 bp fragment) was kindly provided by Dr J H Nielsen (Hagedorn Research Institute, Gentofte, Denmark). The yeast 18S ribosomal cDNA probe was a gift from Dr M Kalousek (University Hospital Zürich).

All PCRs were performed in a GeneAmp PCR System (9600; Perkin Elmer Corp., Norwalk, CT, USA) cycler in 1.5 mmol/l MgCl2, 0.2 μmol/l each primer, 200 μmol/l each dNTP, and 1U Taq polymerase (Qbiogene Inc., Basel, Switzerland) as recommended by the supplier. The amplification conditions were optimized to achieve linear PCR signals. For glucagon they were: one cycle of 1 min at 95°C, 45 s at 59°C, 1 min at 72°C; 33 cycles of 45 s at 95°C, 45 s at 59°C, and 1 min at 72°C, followed by a final extension step of 5 min at 72°C. For IGF-I they were: one cycle of 1 min at 95°C, 45 s at 59°C, 1 min at 72°C; 35 cycles of 45 s at 95°C, 40 s at 60°C, and 1 min at 72°C, followed by a final extension step of 5 min at 72°C. The PCR products were then analysed by electrophoresis on 1.5% agarose gels and purified using a PCR Purification Kit (Qiagen, Basel, Switzerland) according to the manufacturer’s instructions.
The rat insulin, IGF-I, glucagon and yeast 18S ribosomal cDNA probes were labelled by random primer extension using a commercial kit (Boehringer Mannheim, Rotkreuz, Switzerland) and [α-32P]deoxy-CTP (3000 Ci/mmole: Amersham, Cardiff, UK) to specific activities of 2 – 4 x 10^6 c.p.m./µg DNA, following the manufacturer’s instructions.

**Northern blotting**

Total RNA was isolated from pancreatic tissues using a commercial kit (see above). Twenty micrograms heat-denatured (65 °C, 15 min) RNA samples were electrophoresed on a 1% agarose gel containing 2 mol/l formaldehyde, transferred to nylon membranes (Hybond-N, Amersham) by capillary blotting, and fixed by UV cross-linking. Membranes were prehybridized at 42 °C in a solution containing 50% (vol/vol) deionized formamide, 5 × Denhardt’s solution [0.02% (wt/vol) Ficoll and 0.02% (wt/vol) polyvinyl pyrrolidone], 5 × SSPE (20 × 3.6 mol/l NaCl, 0.2 mol/l sodium phosphate, 0.02 mol/l EDTA, pH 7.7), 0.2% SDS and 100 µg/ml heat-denatured salmon sperm DNA. Hybridizations were performed in the same solution with ~2 × 10^7 c.p.m. labelled cDNA probe for insulin, IGF-I, glucagon and 18S cDNA per membrane.

After 48 h of incubation at 42 °C, the membranes were washed twice for 10 min at room temperature, and for 15 min at 54 °C (insulin, IGF-I), 51 °C (glucagon) or 65 °C (18S) in 0.1 × SSC–0.1% SDS. Membranes were then exposed at ~80 °C to an X-Omat AR-5 film (Kodak, Rochester, NY, USA) in cassettes equipped with intensifying screens to visualize [32P]cDNA–mRNA hybrids. Levels of mRNA were quantitated by scanning densitometry using a BioRad video densitometer (Richmond, CA, USA). Between consecutive hybridizations, the membranes were washed with 0.1 × SSC–0.1% SDS at 98 °C for 45 min to remove previous cDNA probe. Variations of gel loading were corrected against 18S ribosomal RNA values.

**Statistical analysis**

All results are expressed as mean ± S.E.M. Statistical analysis was performed by analysis of variance (significance level <0.05) with a StatView 4.5 program (Abacus Concepts, Inc., Berkeley, CA, USA).

**Results**

**Body weight and pancreatic weight**

GH and IGF-I treatment of the hypox rats resulted in a significant increase in body weight (12.67 ± 1.65 g and 7.50 ± 1.18 g respectively) within 2 days, whereas vehicle-treated hypox rats lost 4.33 ± 0.49 g. Neither GH nor IGF-I caused significant changes in pancreas weight.

**Serum glucose**

The serum glucose concentration in hypox rats was 8.65 ± 0.41 mmol/l. GH treatment did not cause any change (8.30 ± 0.18 mmol/l), whereas IGF-I treatment decreased serum glucose slightly, to 7.10 ± 0.12 mmol/l (P = 0.001).

**Serum GH**

Serum concentrations of infused rhGH were 50.9 ± 5.4 ng/ml.

**Serum insulin and C-peptide concentrations, pancreatic insulin peptide and mRNA contents**

Serum insulin concentrations were significantly lower (39 ± 2 pmol/l) in the IGF-I-treated group than in the vehicle-treated group (162 ± 25 pmol/l, P = 0.0001; Fig. 1a). GH did not significantly affect serum insulin (120 ± 15 pmol/l). The decrease in circulating insulin after IGF-I was accompanied by a drastic decrease in serum C-peptide, from 377 ± 57 pmol/l to 39 ± 7 pmol/l (P = 0.0006, Fig. 1b). Serum C-peptide remained unchanged after GH (355 ± 77 pmol/l). GH treatment increased the pancreatic insulin content from 176 ± 28 µg/g to 241 ± 18 µg/g pancreas (+37%, P = 0.009) and total insulin content per pancreas from 47.6 ± 2.3 µg to 63.4 ± 4.5 µg (+33%, P = 0.018), whereas IGF-I did not affect the pancreatic insulin content (188 ± 15 µg/g pancreas; Fig. 1c) or the total insulin content per pancreas (57.2 ± 5.3 µg/pancreas, P = 0.16). No significant changes in the pancreatic insulin mRNA levels were observed after GH or IGF-I treatment (Fig. 1d).

**Serum IGF-I, pancreatic IGF-I peptide and mRNA contents**

Serum IGF-I concentrations were significantly increased, from 161 ± 15 ng/ml to 1889 ± 128 ng/ml (P < 0.0001) by GH and to 586 ± 42 ng/ml (P = 0.0017) by IGF-I treatment (Fig. 2a). Both GH and IGF-I also increased the IGF-I content of the pancreas, from 184 ± 9 ng/g to 288 ± 13 ng/g and 247 ± 9 ng/g respectively (P < 0.0001 and 0.0017 respectively; Fig. 2b). Each of these values was corrected for the IGF-I present in the blood serum retained in the pancreas (24 µl/g pancreas). GH treatment resulted in a marked (83%) increase in pancreatic IGF-I mRNA (P < 0.0001), whereas infused IGF-I did not affect pancreatic IGF-I gene expression (Fig. 2c).

**Serum glucagon, pancreatic glucagon peptide and mRNA contents**

GH treatment did not significantly change serum glucagon concentrations (37.2 ± 3.6 pmol/l as compared
with 41.9±6.0 pmol/l in hypox controls), but IGF-I treatment caused a significant decrease, to 25.3±1.3 pmol/l (P = 0.012; Fig. 3a). GH significantly increased the pancreatic glucagon content, from 11.15±0.94 mg/g to 14.86±1.44 mg/g pancreas (P = 0.036), whereas the increase after IGF-I treatment was not statistically significant (Fig. 3b). Neither GH nor IGF-I caused significant changes in pancreatic glucagon mRNA (Fig. 3c).

**Immunofluorescence**

Insulin immunoreactivity in the β-cells was faint in islets from hypox and IGF-I-treated hypox rats (Fig. 4a,c,d,f), but the staining intensity was markedly increased after GH treatment (Fig. 4b,e). Immunostaining for IGF-I, which appeared to be located in α-cells as shown previously (11), was weak in hypox rats (Fig. 4a) and more intense in islets from GH-treated (Fig. 4b) but not from IGF-I treated rats (Fig. 4c). Similarly, glucagon immunoreactivity was more pronounced in the α-cells of GH-treated rats (Fig. 4e) than in islets of hypox (Fig. 4d) or IGF-I-treated rats (Fig. 4f).

**Discussion**

The present study addressed the question whether endogenous IGF-I induced by GH replacement and exogenously replaced IGF-I elicit the same effect on the endocrine pancreas of the hypox rat. To this end, we investigated the serum concentrations of glucose, IGF-I, insulin, C-peptide and glucagon, and the expression of IGF-I, insulin and glucagon mRNAs and peptides, in pancreatic tissue after a 2-day infusion of GH and IGF-I respectively. The 2-day period of infusion was chosen on the basis of earlier experiments that had shown that maximal steady-state growth effects on the tibial growth plate were achieved after 2 days of GH or IGF-I treatment (12). As in our previous infusion studies in hypox rats (9, 12–14), no attempt was made to substitute thyroxine, cortisone or testosterone in our experimental animals.

GH treatment increased pancreatic IGF-I mRNA, as originally reported by Hynes et al. (15), whereas IGF-I infusion did not affect the expression of IGF-I mRNA. Both GH and IGF-I increased circulating and pancreatic IGF-I but, in contrast to GH, IGF-I substantially reduced serum insulin and C-peptide concentrations (−76% and −90% respectively), suggesting that it strongly...
inhibited insulin secretion. It is unlikely that decreased insulin concentrations were caused by enhanced insulin degradation, because the insulin/C-peptide ratio increased from 1:2.5 and 1:3 in control and in GH-treated animals respectively to 1:1 in the IGF-I-infused animals, suggesting that the insulin half-life in the latter was prolonged rather than decreased. This is also in line with reports that IGF-I inhibited insulin degradation in cultured human hepatoma cells (16) and in preparations of rat liver and rat kidney plasma membranes (17, 18). Furthermore, a 20–30% increase in glomerular filtration, which has been shown in IGF-I-treated rats (19), would hardly account for the dramatic decrease in serum insulin and C-peptide concentrations. We therefore interpret the latter to be the result of inhibition of insulin secretion, compatible with most reports in the literature (see below).

Insulin mRNA expression and pancreatic insulin content were not significantly changed by IGF-I treatment, as also confirmed by immunohistochemistry. However, these data do not allow conclusions to be drawn as to whether or not insulin biosynthesis at the transcriptional and translational levels was significantly affected by IGF-I treatment. As with insulin, the serum glucagon concentrations also were reduced by IGF-I, although less so (~40%) than those of insulin, again without significant changes in pancreatic glucagon mRNA or peptide expression.

The findings obtained with GH showed essential differences from those observed with IGF-I infusion: although GH, like IGF-I, increased both circulating and pancreatic IGF-I, it did not affect serum glucose, insulin, C-peptide and glucagon, whereas it increased pancreatic insulin and glucagon content. These differences demonstrate that the effects of infused IGF-I in the absence of GH are not mimicked by endogenous circulating or pancreatic IGF-I induced by GH replacement. In contrast to these results in hypox rats, human studies in GH-deficient patients have shown that GH replacement increases serum insulin and glucose concentrations and reduces insulin sensitivity (5). The discrepancy between these results is due to the fact that GH-deficient patients received other hormone replacement therapy in addition to GH.

Inhibition of insulin secretion by IGF-I has been shown both in vitro and in vivo. In the isolated perfused rat pancreas (20) and in purified rat β-cells (21), addition of IGF-I potently suppressed insulin secretion, suggesting a direct effect of IGF-I on the
Localization of insulin (red fluorescence), IGF-I (a–c, green fluorescence) and glucagon (d–f, green fluorescence) revealed by double immunofluorescence in pancreatic islets from (a,d) hypox controls, (b,e) GH-treated and (c,f) IGF-I-treated hypox rats. In brief, pancreatic peptides were stained with primary antisera directed against insulin (a–f) and IGF-I (a–c) or glucagon (d–f), followed by fluorescence-coupled secondary antibodies. Microscopic images were obtained by confocal laser scanning. Bar represents 70 μm.

Figure 3 (a) Serum glucagon, (b) pancreatic glucagon content and (c) glucagon mRNA levels of hypox controls (HYP) and GH- and rhIGF-I- treated hypox rats. Serum and pancreatic glucagon were measured by a specific rat glucagon RIA; glucagon mRNA was determined by northern analysis. Northern blot signals for glucagon mRNA and 18S rRNA are shown above the corresponding columns for each of the treatment groups. Glucagon mRNA signals were normalized against 18S rRNA signals and expressed as relative levels. Columns give the mean values (n = 6) and bars represent s.e.m. Significance levels (P) are shown.

Figure 4 Localization of insulin (red fluorescence), IGF-I (a–c, green fluorescence) and glucagon (d–f, green fluorescence) revealed by double immunofluorescence in pancreatic islets from (a,d) hypox controls, (b,e) GH-treated and (c,f) IGF-I-treated hypox rats. In brief, pancreatic peptides were stained with primary antisera directed against insulin (a–f) and IGF-I (a–c) or glucagon (d–f), followed by fluorescence-coupled secondary antibodies. Microscopic images were obtained by confocal laser scanning. Bar represents 70 μm.
β-cell. However, no inhibition of insulin release by IGF-I was observed in tissue cultures of human pancreatic islets (22), and both stimulation and inhibition of insulin release have been reported in isolated perfused rat islets, depending on the perfusion conditions (23). Inhibition of glucose-stimulated glucagon-like peptide I-stimulated insulin secretion by IGF-I has been demonstrated in rat pancreatic monolayer cells and in the HIT-T15 β-cell line (24). Insulin secretion has also been found to be suppressed in humans infused with IGF-I (5, 25–27). A recent study in IGF-I-infused (6 days) hypox rats receiving l-thyroxine and cortisol substitution demonstrated that serum insulin and C-peptide concentrations were suppressed and that insulin sensitivity in isolated soleus muscle was enhanced (28), which is in line with results from studies in humans (5, 25–27). Our results in IGF-I-infused hypox rats are in agreement with these findings: despite largely reduced serum insulin concentrations, serum glucose did not increase, compatible with increased insulin sensitivity. Reduced serum glucagon concentrations in the IGF-I-infused animals may also have contributed to balancing glucose homeostasis. However, it cannot be excluded that IGF-I exerted additional insulin-like effects. Thus we had found previously that hypox rats infused with IGF-I became hypoglycaemic during the first 8 h of the infusion (29), Blood sugar concentrations increased after 16 h, together with the induction of IGF binding protein (IGFBP)-3 (29), and were not different from those of hypox controls when the infusion lasted for 6 days or longer (9, 12, 13, 28).

The mechanism whereby IGF-I inhibits insulin secretion has been investigated by Zhao et al. (24) in cultures of neonatal rat pancreatic monolayer cells and in the HIT-T15 β-cell line. These authors demonstrated that IGF-I activates phosphodiesterase 3B (PDE 3B) in the β-cells, thereby decreasing the intracellular cyclic AMP concentration and thus inhibiting insulin secretion. On the basis of these in vitro findings, an interesting in vivo feedback model was postulated in which ‘IGF-I inhibition of insulin secretion through activation of PDE 3B may constitute part of a major homeostatic control mechanism for regulation of insulin secretion’ (24). In this model, increased insulin secretion would stimulate IGF-I synthesis and release by the liver, resulting in increased circulating IGF-I, interaction of the latter with the IGF-I receptors on the β-cell, activation of PDE 3B, a decrease in intracellular cyclic AMP and, finally, in attenuation of insulin release. Although part of this model is consistent with our findings in IGF-I-infused hypox rats, it is at variance with our results in the GH-infused animals. Here, stimulation of endogenous circulating or pancreatic IGF-I did not inhibit insulin secretion. In vivo, both circulating and tissue IGF-I are essentially under the control of GH, and increased endogenous IGF-I always occurs in association with increased GH secretion – a situation similar to that in our GH-infused hypox rats. It is, therefore, difficult to distinguish between the potential effects of endogenous IGF-I and the potential direct, IGF-I-independent effects of GH. Furthermore, the question as to what extent endogenous IGF-I reaches the β-cell to interact with IGF-I receptors remains unresolved. As in normal rats, IGF-I in GH-treated hypox rats circulates predominantly as a 150 kDa ternary complex (29), together with IGFBP-3 and an acid-labile subunit (30). The capillary permeability of this complex, and thus the bioavailability of the IGF-I bound to it, seem to be largely restricted (31). This is different in IGF-I-infused hypox rats. Here, the 150 kDa complex is lacking (32) and the infused IGF-I circulates in association with the smaller, 40–50 kDa, binding protein complex, which can pass the capillary bed and deliver the infused IGF-I to IGF-I receptors (32). Thus a quantitative comparison of the circulating IGF-I concentrations in the two infusion conditions does not appear to be straightforward. It was therefore important to determine pancreatic (local) IGF-I concentrations in GH- and IGF-I-infused animals, which may more adequately reflect conditions at the tissue level. We found that both GH and IGF-I treatment increased IGF-I in the pancreatic tissue, GH even more than infused IGF-I.

Nevertheless, two questions remain unanswered. Firstly, why does the GH-induced increase in endogenous pancreatic IGF-I not affect insulin secretion in the same way as the increase in pancreatic IGF-I caused by rhIGF-I infusion? Pancreatic IGF binding proteins (as determined by western ligand blotting of pancreatic extracts), which could be responsible for the discrepancy in insulin secretion discussed above, were nearly undetectable in the treated animals after 9 days of exposure of the membrane to the X-ray film (not shown). Therefore, one possible explanation may be that GH counteracts locally produced IGF-I in the pancreas by a direct, IGF-I-independent mechanism. Another explanation would be that the actions of infused IGF-I on muscle and of GH on liver, fat and muscle metabolism result in opposite effects on glucose availability. These effects probably contribute to insulin needs and thus to the observed differences in serum insulin concentrations between our IGF-I- and GH-treated animals. The second question is why GH replacement and IGF-I infusion act in concert on skeletal growth of hypox rats, whereas they do not with respect to insulin secretion. To date, IGF research has not offered any explanation for these apparently puzzling inconsistencies.

In summary, our results show that infused IGF-I in the absence of GH does not affect pancreatic insulin mRNA and peptide expression, but strongly reduces serum insulin concentrations, which suggests that it inhibits insulin secretion and enhances insulin sensitivity. Endogenous GH-induced circulating or pancreatic IGF-I does not act on the endocrine pancreas in analogy to administered IGF-I.
Acknowledgements

We thank Mrs Gunthild Krey and Mrs Cornelia Zwimpfer for skilful technical assistance. The work was supported by grants nos 32-46808.96 and 32.61481.00 of the Swiss National Science Foundation, and by the Hartmann-Müller Stiftung für Medizinische Forschung of the University of Zürich.

References


Received 15 January 2004
Accepted 20 April 2004